Orbillion Bio is a biotechnology company that develops therapies for cancer and other diseases. The company's lead product candidate, ORB-204, is a novel, orally available small molecule inhibitor of the Wnt signaling pathway, which is implicated in the development and progression of multiple types of cancer. Orbillion Bio is also developing a pipeline of other small molecule inhibitors of Wnt signaling, as well as other targets in oncology and other therapeutic areas. The company was founded in 2019 and is headquartered in Brisbane, California.